Why Genetic Testing Should Be Standard in Prostate Cancer

Labcorp, Rebecca Previs, Sarah Young, genetic counselor, genetic testing, prostate cancer, urologic oncology, germline, somatic, PARP inhibitors, digital

Hear why universal genetic testing matters in prostate cancer — plus, how it can improve treatment, equity, and outcomes for patients everywhere.

May 18^th • 19 mins listen

How Cross-Functional Teams Reshape Cancer Care

Jay Fine, Preclinical Research, Early Stage

In episode 3 of Oncology Voice Network Podcast, Dr. Kirk Shepard sits down with Dr. Jay Fine, a renowned immunologist and President of R&D at Evolve Immune Therapeutics and a Forbes-published author in Voices of Oncology, for a candid look at how discovery truly connects to patient care.

Feb 17^th • 23 mins listen

New Guidelines for Managing Immunotherapy-Related Adverse Events

ONS’s Pamela Ginex, EdD, MPH, RN, OCN®, discusses the new immunotherapy toxicity guidelines released by the National Comprehensive Cancer Network and the American Society of Clinical Oncology. We talk about ONS’s role in helping to develop the information, the importance of educati…

Feb 19^th • 13 mins listen

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Highlights From Today’s Episode “With next-generation sequencing (NGS), multiple biomarkers can be evaluated using one test. So, in cancer care, we’re learning that any given tumor may harbor a variety of variants. So, if we’re considering using in situ hybridization (ISH)…

Mar 30^th • 47 mins listen

Oncology Pharmacology 2023: Today’s Treatments and Tomorrow’s Breakthroughs

CDER, FDA, Nurses, biomarker, immunomodulatory

Highlights From Today’s Episode “Full approval through the Center for Drug Evaluation and Research (CDER) and FDA means that those drugs have gone through the laboratory testing, human clinical trial testing, and very extensive clinical trials to make sure that they are effective and th…

Mar 30^th • 53 mins listen